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Abstract 
Background: Hyperglycemia and insulin resistance often develop cardiovascular and nephrological dysfunction 
in diabetic patients. Sitagliptin is used to treat diabetes and showed potential benefit in lowering increased blood 
glucose level in diabetes. This investigation reports the effect of sitagliptin treatment on oxidative stress in kidney and 
heart of 2K1C rats.
Methods: Male Long Evans rats underwent unilateral surgical stenosis of the renal artery [2-kidney-1-clip (2K1C) 
method]. These animals entered a 4-weeks dosing period with sitagliptin. Blood and urine sampling and organ 
harvesting were finally performed. Blood plasma, heart, kidney tissues and urine were tested for the assessment of 
inflammation and oxidative stress in kidney and heart of 2K1C rats after 4 weeks of surgery.
Results: 2K1C rats showed cardiac hypertrophy, increased left ventricular wet weight compared to sham which was 
not significantly altered by sitagliptin treatment. Uric acid and creatinin concentrations were also increased in 2K1C 
rats. Sitagliptin significantly prevented the elevation of uric acid and creatinin concentration in plasma and urine in 
this rat model. Oxidative stress markers in plasma such as malondialdehyde (MDA), nitric oxide (NO), and advanced 
protein oxidation product (APOP) concentrations were increased in the 2K1C rats as compared to sham-operated 
animals. Increased concentrations of these oxidative stress markers were also normalized by sitagliptin treatment. 
2K1C rats also showed increased level of uric acid and creatinine both in plasma and urine; which are also reduced to 
normal level in sitagliptin treated rats. Moreover, 2K1C surgery initiated inflammatory cell infiltration, increased MPO 
activity and fibrosis in both heart and kidneys which were further ameliorated by sitagliptin treatment.
Conclusion: Our study suggests that sitagliptin treatment in 2K1C rats prevented inflammation and fibrosis of heart 
and kidney by ameliorating elevated oxidative stress in heart and kidney tissues.
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Background
Congestive heart failure and kidney dysfunction are 
major causes of mortality and morbidity in patient suf-
fering diabetes worldwide [1, 2]. These secondary 
complications are frequently seen in most of the diabetes 
patients and become a public health concern now a day. 
Myocardial remodeling occurs during the progression 
of cardiomyopathy in diabetes and possesses an impor-
tant role in the pathophysiology of hypertensive disease   
[3]. Myocardial cell apoptosis, necrosis, hypertrophy and 
extension have been noted during the progression of 
myocardial remodeling and cardiac hypertrophy [4, 5]. 
Moreover, myocardial extracellular matrix and collagen 
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fiber deposition are also found in hypertrophied heart 
both in experimental animals [6] and in clinical experi-
ments [7]. Free radical mediated oxidative stress is con-
sidered as a key player in cardiaomyocyte hypertrophy 
which can be prevented by antioxidant treatment [8, 9]. 
The sources of reactive free radicals in heart are mito-
chondrial electron transport chain, inducible nitric oxide 
synthase, NADPH oxidase and xanthine oxidase [10]. 
Oxidative stress mediated insult in the mayocardium 
also attract inflammatory cells [11]. Several reports also 
suggest that NADPH oxidase containing neutrophil infil-
tration in myocardium is mainly responsible for free radi-
cals mediated oxidative stress in heart [9, 12].
Plasma renin release and Ang II activity are increased 
in case of kidney ischemia [13]. Type 2 diabetes patients 
often suffer hypertension due to the over activity of renin 
angiotensin system. Renin angiotensin system plays a 
crucial role in many pathophysiology of cardiac oxidative 
stress and myocardial remodeling in diabetes [14]. The 
two-kidney one-clip (2K1C) renovascular hypertension 
model animal showed elevated circulating levels of Ang 
II with high Ang II concentrations in the cortical tissue of 
the clipped and nonclipped kidneys [15, 16]. Moreover, 
cross talk between free radicals production and ang-II 
mediated hypertrophied response in heart is well docu-
mented and reviewed recently [8]. Previous studies have 
reported that angiotensin II (Ang II) stimulates the pro-
duction of reactive oxygen species (ROS) such as super-
oxides [17, 18]. In experimental 2K1C hypertension, the 
overproduction of reactive oxygen species (ROS) may 
lead to oxidative stress and increased lipid peroxidation 
[19, 20]. Increased ANG II activity and oxidative stress 
further triggers the deposition of extracellular matrix and 
fibrosis in heart and kidney of 2K1C model animal [21, 
22].
Dipeptidyl peptidase-4 (DPP-4) inhibitors are used 
for the treatment of the Type 2 diabetes mellitus 
(T2DM). Sitagliptin belongs to DPP-4 inhibitors group 
that prevent the degradation of insulinotropic incretin 
glucagon like peptide (GLP-1), without producing hypo-
glycemia [23]. DPP-4 inhibitors also preserves islet func-
tion in both type 1 and type 2 diabetes animal models and 
increases pancreatic insulin content, through an increase 
in proliferation, neogenesis, and apoptosis resistance of 
beta cells [24]. Previous studies suggest that DPP-4 inhib-
itors prevent cardiac diastolic dysfunction and ameliorate 
glomerulopathy in insulin-resistant Zucker obese rats 
[25, 26]. Improved endothelium-dependent relaxation 
function in renal arteries, restored renal blood flow and 
reduced systolic blood pressure was observed in spon-
taneously hypertensive rats by 2  weeks treatment with 
sitagliptin [27]. However, sitagliptin appears to limit the 
blood pressure lowering effect of enalapril in patients 
with metabolic syndrome [28]. Some other studies also 
demonstrated the beneficial impact of sitagliptin on dia-
betic nephropathy [29–31]. Therefore, it is of particular 
interest to examine whether DPP-4 inhibitor can sup-
press oxidative stress and inflammation in heart and kid-
ney of two kidney one clip (2K1C) rats.
Methods
Chemicals and reagents
Sitagliptin were obtained from Beximco Pharmaceuticals 
Limited (Bangladesh) as gift sample. Thiobarbituric acid 
(TBA) was purchased from Sigma Chemical Company 
(USA). Trichloroacetic acid (TCA) was purchased from 
J.I. Baker (USA). Alanine aminotransferase (ALT), aspar-
tate aminotransferase (AST), alkaline phosphatase (ALP), 
and uric acid (UA) assay kits were obtained from DCI 
diagnostics (Budapest, Hungary). All other chemicals and 
reagents used were of analytical grade.
Animal’s surgery and treatment
Twelve to fourteen weeks old, 24 Long Evans male rats 
(170–230  g) were obtained from Animal production 
unit of Animal House at Department of Pharmaceuti-
cal Sciences, North South University and were kept in 
ordinary cages at room temperature of 25 ± 3 °C with a 
12  h dark/light cycles with food water ad  libitum. They 
have free access to food and water, according to the study 
protocol approved by Ethical Committee of Department 
of Pharmaceutical Sciences, North South University for 
animal care and experimentation. To study the effects of 
sitagliptin, rats were equally divided into four groups (six 
rats in each group): Sham, Sham + sitagliptin, 2K1C and 
2K1C + sitagliptin. Rats were subjected to unilateral clip-
ping of the renal artery to produce two kidney one clip 
(2K1C) model rats. In brief, a left kidney was exposed 
via laparotomy. The left renal artery was separated from 
the left renal vein and a silk ligature placed around the 
renal artery. A 23-gauge injection needle was placed into 
the ligature, parallel to the renal artery, the ligature tied 
and the needle carefully removed. Visual assessment 
of kidney perfusion was performed before closing the 
wound. Sham-operated rats underwent the same proce-
dure, but kidneys were only mobilized and renal vessels 
were only separated instead of being partially ligated. All 
procedures were performed under intraperitoneal injec-
tion of ketamine anesthesia. Animals were transferred to 
the housing facility and monitored once they recovered 
from anesthesia. After surgery, rats were received nor-
mal food and water for 28 days. Sham +  sitagliptin and 
2K1C +  sitagliptin groups received sitagliptin (100  mg/
kg, daily) by oral gavaging. Animals were checked for 
the body weight and water intake on a daily basis. After 
4 weeks of treatment with or without sitagliptin, the rats 
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were placed in metabolic cages, and urine was collected 
for 24 h. The urine volume was measured for every rat. 
After 28 days of the last treatment, all the animals were 
weighed, sacrificed, collected the blood and organs like 
heart, kidney, spleen and liver. Immediately after collec-
tion of these tissues and organs, they are weighed and 
stored at −20 °C for further analysis.
Assessment of AST, ALT and ALP activities
Liver marker enzymes (alanine aminotransferase (ALT), 
aspartate aminotransferase (AST), and alkaline phos-
phatase (ALP) were estimated in plasma by using Diatech 
diagnostic kits for AST, ALT and ALP (Hungary) accord-
ing to the manufacturer’s protocol. Uric acid and creati-
nine were also measured using Diatech diagnostic kits for 
uric acid and creatinin (Hungary) according to the manu-
facturer’s protocol.
Assessment of oxidative stress markers
For determination of oxidative stress markers, heart and 
kidney tissue was homogenized in 10 volumes of Phos-
phate buffer containing (pH 7.4) and centrifuged at 
12,000×g for 30  min at 4  °C. The supernatant was col-
lected and used for the determination of protein and 
enzymatic studies as described below.
Estimation of lipid peroxidation product malondialdehyde 
(MDA)
Plasma concentrations of malondialdehyde are an index 
of lipid peroxidation and oxidative stress. Lipid peroxi-
dation in heart and kidney were estimated colorimetri-
cally measuring malondialdehyde followed by previously 
described method [32]. In brief, 0.1  mLentrated Acetic 
Acid-HCl reagent (thiobarbituric acid 0.37 %, 0.25 N HCl 
and 15 % TCA) and placed in water bath for 15 min and 
cooled. The absorbance of clear supernatant was meas-
ured against reference blank at 532 nm.
Estimation of nitric oxide (NO)
NO was determined according to the method described 
by Tracy et  al. as nitrate and nitrite [33]. In this study, 
Griess-Illosvoy reagent was modified by using naphthyl 
ethylene diamine dihydrochloride (0.1 % w/v) instead of 
1-napthylamine (5 %). The reaction mixture (3 mL) con-
taining tissue homogenates (2 mL) and phosphate buffer 
saline (0.5  mL) was incubated at 25  °C for 150  min. A 
pink colored chromophore was formed which was meas-
ured at 540 nm.
Estimation of advanced protein oxidation products (APOP)
Determination of APOP levels was performed by modi-
fication of the method of Witko-Sarsat [34] and [35] 
Tiwari. Two mL of plasma was diluted 1:5 in PBS: 0.1 mL 
of 1.16 M potassium iodide was then added to each tube, 
followed by 0.2 mL acetic acid after 2 min. The absorb-
ance of the reaction mixture was immediately read at 
340 nm against a blank containing 2 mL of PBS, 0.1 mL 
of potassium iodide (KI), and 0.2 mL of acetic acid. The 
chloramine-T absorbance at 340 nm being linear within 
the range of 0–100 mmol/L, APOP concentrations were 
expressed as μmol L−1 chloramine-T equivalents.
Estimation of catalase (CAT) activity
CAT activities were determined by the method of Chance 
and Maehly [36, 37] with some modifications. The reac-
tion solution of CAT activities contained: 2.5  ml of 
50 mmol phosphate buffer (pH 5.0), 0.4 mL of 5.9 mmol 
H2O2 and 0.1  mL enzyme extract. Changes in absorb-
ance of the reaction solution at 240 nm were determined 
after 1 min. One unit of CAT activity was defined as an 
absorbance change of 0.01 as units/min.
Estimation of myloperoxidase (MPO) activity
MPO activity was determined by a dianisidine-
H2O2  method [38], modified for 96-well plates. Briefly, 
plasma samples (10 μg protein) were added in triplicate 
to 0.53  mM  o-dianisidine dihydrochloride (Sigma) and 
0.15  mM H2O2  in 50  mM potassium phosphate buffer 
(pH 6.0). The change in absorbance was measured at 
460  nm. Results were expressed as units of MPO/mg 
protein.
Histopathalogical determination
For microscopic evaluation heart and kidney tissues were 
fixed in neutral buffered formalin and embedded in par-
affin, sectioned at 5  μm and subsequently stained with 
hematoxylin and eosin (H & E) to evaluate inflammatory 
cell infiltration. Sirius red staining was also performed 
to evaluate the fibrosis in heart and kidney. Moreover, 
Prussian blue staining was done to determine the iron 
deposition in tissues. Sections were studied under light 
microscope at 40× magnifications.
Statistical analysis
The values are expressed as mean ±  standard deviation 
(SD). The results were evaluated by using the Two-way 
ANOVA followed by Bonferroni test using Graph Pad 
Prism Software, USA, version 6. Statistical significance 
was considered as p < 0.05 in all cases.
Results
Effect of sitagliptin on body weight, food and water intake 
in 2K1C rats
Body weight of each rat was recorded every day dur-
ing the experiment, and  % change was calculated for 
all groups. It was found that the body weight increased 
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consistently in sitagliptin treated rats group, which is 
denoted that the treatment have no effect on the body 
weight. On the other hand sham  +  sitagliptin group 
showed no variation in their body weight. Water intake 
was not changed significantly among the groups.
Effect of sitagliptin on organ wet weight in 2K1C rats
Table  1 shows the effect of various treatments on the 
rats’ organs wet weight. The wet weight of heart and kid-
ney was increased in the 2K1C rats when compared with 
sham rats. Left ventricular wet weight was increased 
significantly compared to sham rats. However, sitaglip-
tin treatment showed no significant change in the wet 
weight of the left ventricle of heart in the 2K1C rats. 
Neither 2K1C challenge and nor sitagliptin treatment in 
rats have changed the right ventricular wet weight sig-
nificantly compared to sham rats. 2K1C rats also showed 
slight decrease in liver wet weight, however, sitagliptin 
treatment did not altered the wet weight of the liver com-
pared to 2K1C rats. Another crucial finding in this study 
was that 2K1C rats showed increased kidney wet weight 
compared to sham rats which were unaltered by sitaglip-
tin treatment (Table 1). Furthermore, 2K1C rats showed 
increased spleen wet weight compared to sham rats which 
were reduced by sitagliptin treatment in 2K1C rats.
Effect of sitagliptin on biochemical parameters AST, ALT 
and ALP activity
Biochemical measurement of 2K1C rats showed a signifi-
cant increase in plasma AST, ALT, and ALP activity com-
pared to sham rats (Table 2). Treatment with sitagliptin 
in 2K1C rats significantly counteracted these increased 
enzymes activity. In addition, treatment of animals with 
sitagliptin alone for 4 weeks did not show any significant 
changes in AST, ALT and ALP enzyme activities com-
pared to the sham rats (Table 2).
Effect of sitagliptin on oxidative stress markers 
and antioxidant enzymes
To determine the oxidative stress in our study, we evalu-
ated the malondialdehyde (MDA), nitric oxide and 
advanced protein oxidation product (APOP) content in 
plasma, heart and kidneys. 2K1C rats showed a higher 
concentration of lipid peroxidation product MDA in 
plasma, heart and kidney (Tables  2, 3). Additionally, sit-
agliptin treatment in 2K1C rats significantly reduced 
the level of lipid peroxides compared to 2K1C group 
in plasma, heart and kidney. 2K1C rats also showed 
profound effect on APOP development in plasma and 
kidney tissues (Tables  2, 3). 2K1C rats showed signifi-
cantly increase concentration of APOP in plasma and 
kidney which was normalized due to sitagliptin treat-
ment in 2K1C rats. APOP concentration was unchanged 
in all groups tested in this study. Nitric oxide measured 
as nitrate was also increased in plasma, heart and kid-
ney compared to sham rats which were further normal-
ized by sitagliptin treatment in 2K1C group (Tables  2, 
3). 2K1C group rats showed decrease in antioxidant 
enzyme catalase activity compared to the sham group rats 
(Tables 2, 3). Treatment with sitagliptin to 2K1C signifi-
cantly counteracted the oxidative stress by restoring the 
catalase activity to near normal compared to 2K1C group 
(Tables 2, 3).
Effect of sitagliptin on uric acid and creatinine 
concentration in plasma and urine
Uric acid concentration in plasma and urine was 
increased in 2K1C rats significantly compared to the 
sham rats. Sitagliptin treatment in these rats lowered the 
uric acid concentration significantly compared to 2K1C 
rats group. Sitagliptin treatment in sham rats did not 
change uric acid concentration in plasma compared to 
sham rats.
Table 1 Effect of sitagliptin on body weight, food and water intake and organ weight of 2K1C rats
Values are presented as mean ± SEM. Two way or One way ANOVA with Bonferoni tests were done as post hoc test
Values are considered significance at p < 0.05. (Organ wet weights are expressed as gm/100 gm of body weight)
Parameter Sham Sham + Sitagliptin 2K1C 2K1C + Sitagliptin p values
2K1C Treatment Interaction
Initial body weight (gm)178.07 ± 6.80 218.40 ± 7.49 214.26 ± 3.39 231.17 ± 11.42 0.0023 0.0073 0.1671
Final body weight (gm) 224.75 ± 14.86 229.55 ± 4.77 269.10 ± 10.56 251.47 ± 12.66 0.5833 0.0095 0.3415
Water intake/d 18.61 ± 1.10 15.69 ± 0.43 20.64 ± 0.72 22.58 ± 0.80 0.5529 <0.0001 0.0074
Liver wet weight 3.24 ± 0.10 3.59 ± 0.24 3.22 ± 0.24 3.72 ± 0.12 0.0310 0.7663 0.6855
Kidney wet weight 1.40 ± 0.07 1.62 ± 0.06 2.36 ± 0.11 2.50 ± 0.18 0.1382 <0.0001 0.7347
Heart wet weight 1.29 ± 0.07 1.45 ± 0.04 1.59 ± 0.05 1.40 ± 0.08 0.0576 0.8114 0.0106
Left ventricle wt. 1.03 ± 0.03 1.06 ± 0.02 1.24 ± 0.07 1.16 ± 0.07 0.0081 0.6402 0.3089
Right ventricle wt. 0.16 ± 0.02 0.23 ± 0.01 0.24 ± 0.02 0.20 ± 0.02 0.1808 0.4152 0.0063
Spleen wet weight 1.37 ± 0.16 1.58 ± 0.16 2.39 ± 0.66 2.00 ± 0.17 0.2505 0.0774 0.1647
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2K1C rats also showed increased creatinin concentra-
tion both in plasma and urine significantly compared to 
sham rats. Sitagliptin treatment normalized the creatinin 
concentration in plasma and urine of 2K1C rats.
Effect of sitagliptin on inflammation and fibrosis markers 
in heart and kidneys
Inflammation was seen in rats of 2K1C group compared 
to sham rats. To determine inflammation in tissues, we 
measured myloperoxidase (MPO) activity in heart and 
kidney tissues. 2K1C group rats showed increased MPO 
activity both in heart and kidney compared to sham rats. 
Sitagliptin treatment significantly normalized the MPO 
activity in 2K1C rats compared to sham rats. These data 
are further supported by the histological assessment of 
tissue sections of heart and kidneys. Necrotized tissue 
scar and ballooning of the cardiomyocytes were also seen 
in heart of 2K1C rats (Fig.  1). Sitagliptin treatment sig-
nificantly attenuated the inflammatory cell infiltration 
and necrosis in the heart tissues of 2K1C rats (Fig.  1). 
Table 2 Effect of sitagiliptin on biochemical parameters in plasma and urine of 2K1C rats
Values are presented as mean ± SEM. Two way or One way ANOVA with Bonferoni tests were done as post hoc test
APOP advanced protein oxidation product, expressed as nmol/mL equivalent to Chloramine-T
Values are considered significance at p < 0.05
Parameters Sham Sham + Sitagliptin 2K1C 2K1C + Sitagliptin p values
2K1C Treatment Interaction
Plasma
 AST (U/L) 26.97 ± 1.25 24.42 ± 0.67 35.27 ± 1.29 27.08 ± 0.58 <0.0001 <0.0001 0.0107
 ALT (U/L) 18.32 ± 0.94 20.77 ± 0.76 35.27 ± 1.29 24.35 ± 0.42 0.0002 <0.0001 <0.0001
 ALP (U/L) 43.30 ± 1.22 40.83 ± 1.92 56.23 ± 2.49 50.97 ± 1.72 0.0546 <0.0001 0.4697
 MDA (nmol/mL) 5.03 ± 0.20 6.58 ± 0.32 8.13 ± 0.24 3.72 ± 0.12 0.0004 <0.0001 0.0630
 NO (nmol/mL) 2.82 ± 0.12 3.30 ± 0.31 7.78 ± 0.28 5.20 ± 0.21 0.0003 <0.0001 <0.0001
 APOP (ng/mL) 102.45 ± 4.30 129.53 ± 4.73 304.96 ± 10.55 223.33 ± 8.97 0.0019 <0.0001 <0.0001
 CATALASE (U/L) 5.42 ± 0.08 5.37 ± 0.13 3.43 ± 0.20 4.05 ± 0.29 0.1532 <0.0001 0.0963
 Uric acid (mg/dL) 4.93 ± 0.54 6.24 ± 0.72 12.18 ± 1.15 8.41 ± 0.75 <0.0001 0.1535 0.0070
 Creatinin (mg/dL) 1.36 ± 0.10 1.56 ± 0.05 2.30 ± 0.20 1.46 ± 0.31 0.0158 0.1163 0.0446
Urine
 Uric acid (mg/dL) 6.25 ± 0.18 4.18 ± 0.25 8.25 ± 0.33 6.78 ± 0.23 <0.0001 <0.0001 0.2536
 Creatinin (mg/dL) 10.76 ± 0.54 5.60 ± 0.82 18.90 ± 2.73 7.03 ± 1.18 0.0062 <0.0001 0.0446
Table 3 Effect of sitagiliptin on oxidative stress parameters in heart and kidney of 2K1C rats
Values are presented as mean ± SEM. Two way or One way ANOVA with Bonferoni tests were done as post hoc test
APOP advanced protein oxidation product, expressed as nmol/mL equivalent to Chloramine-T
Values are considered significance at p < 0.05
Parameter Sham Sham + Sitagliptin 2K1C 2K1C + Sitagliptin p values
2K1C Treatment Interaction
Heart
 MDA (nmol/mL) 47.62 ± 1.76 50.38 ± 3.41 77.08 ± 4.88 61.46 ± 4.06 <0.0001 0.1912 0.0087
 NO (nmol/mL) 13.08 ± 2.52 9.66 ± 0.42 25.21 ± 2.81 21.86 ± 3.67 0.0002 0.2145 0.9896
 APOP (ng/mL) 227.30 ± 32.31 230.48 ± 12.34 237.62 ± 22.28 232.86 ± 36.91 0.8246 0.9780 0.8897
 CATALASE (U/L) 7.64 ± 0.31 7.40 ± 0.73 5.48 ± 0.54 7.08 ± 0.60 0.0482 0.2613 0.1338
 MPO Activity (U/mg protein) 2.20 ± 0.09 1.90 ± 0.18 3.77 ± 0.17 2.30 ± 0.17 <0.0001 <0.0001 0.0013
Kidney
 MDA (nmol/mL) 101.38 ± 7.84 124.92 ± 6.92 183.00 ± 10.77 133.51 ± 9.85 0.0001 0.1820 0.0010
 NO (nmol/mL) 13.89 ± 1.28 11.21 ± 1.81 62.36 ± 5.49 52.59 ± 1.93 <0.0001 0.0594 0.2684
 APOP (ng/mL) 391.90 ± 40.11 421.75 ± 24.02 978.57 ± 100.73 348.73 ± 35.44 <0.0001 <0.0001 <0.0001
 CATALASE (U/L) 12.72 ± 1.20 10.50 ± 1.50 6.70 ± 0.38 11.08 ± 1.04 0.0234 0.3416 0.0075
 MPO Activity (U/mg protein) 1.94 ± 0.28 1.79 ± 0.18 2.80 ± 0.22 1.85 ± 0.09 0.0359 0.0141 0.0646
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Moreover, sham rats and sham rats treated with sitag-
liptin showed no inflammatory cells infiltration in left 
ventricle of heart. Massive serge of inflammatory cells 
was found in the glomerular part of 2K1C rats kidney 
sections stained with H & E. Glomerulosclerosis was evi-
dent, and the interstitium showed patchy infiltrates of 
mononuclear cells as well as fibrosis (Fig.  2). However, 
no significant difference could be detected between sham 
rats and 2K1C rats treated with sitagliptin, demonstrat-
ing complete healing of the nephritic changes (Fig.  2). 
Cardiac and kidney fibrosis were evaluated histologically 
by visualizing the red color collagen fibers deposition 
using Sirius red staining process. Sham rats and sham 
rats treated with sitagliptin showed no/less deposition 
of collagen fibers in heart and kidneys. However, 2K1C 
rats showed massive collagen deposition both in heart 
and kidney which was further attenuated by sitagliptin 
treatment (Figs. 3, 4). Furthermore, free iron deposition 
was also seen in kidney sections of 2K1C rats which were 
ameliorated by sitagliptin treatment (Fig. 5). However, no 
iron deposition occurred in left ventricular section of all 
groups tested in this study.    
Discussion
This study demonstrated that sitagliptin treatment pre-
vented the oxidative stress, inflammatory cell infiltra-
tion and fibrosis in heart and kidney of 2 kidney one clip 
(2K1C) rats. Previous studies suggest that, two-kidney, 
one-clip (2K1C) rat model experience a decreased renal 
perfusion pressure which causes the kidney to over-
produce renin and leads to a continual activation of the 
renin–angiotensin–aldosterone axis [39]. Renal artery 
Fig. 1 Effect ofsitagliptin on cardiac inflammation in 2K1C model rats. a Sham; b Sham + Sitagliptin; c 2K1C and d 2K1C + Sitagliptin. No inflam-
matory process was observed in Sham animals (a) and Sham + Sitagliptin (b). Observe the increase of inflammatory cells in the left ventricle of 
heart of 2K1C rats (c, arrows). No/less inflammatory process can be observed in left ventricle of heart of all 2K1C animals treated with sitagliptin (d). 
Magnification ×40. H & E staining. ic inflammatory cells, nc necrotic site
Fig. 2 Effect of sitagliptin on kidney inflammation in 2K1C model rats. a Sham; b Sham + Sitagliptin; c 2K1C and d 2K1C + Sitagliptin. No inflam-
matory process was observed in Sham animals (a) and Sham + Sitagliptin (b). Observe the increase of inflammatory cells in the kidneys of 2K1C (c 
arrows). Glomerular sclerosis, tubular atrophy with accompanying moderate interstitial fibrosis and infiltration by mononuclear cells was also found. 
No/less inflammatory process can be observed in right kidney of 2K1C treated with sitagliptin (d). Magnification ×40. H & E staining. ic inflamma-
tory cells, gc glomerular sclerosis
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constriction, usually from atherosclerotic or fibromuscu-
lar dysplastic renal disease may develop such condition in 
human [40].
Oxidative stress due to excess generation of ROS plays 
an important role in producing tissue damage to the 
organ or increased the inflammatory response which 
ultimately stimulates the production of pro-fibrogenic 
mediators and initiate fibrogenesis. Lipid peroxidation, 
arising from the reaction of free radicals with lipids, 
has been linked with altered membrane structure and 
enzyme inactivation. Its end products are measured as 
TBARS, lipid hydroperoxides and conjugated dienes [41]. 
In our study, all 2K1C groups showed increased serum 
malon dialadehyde (MDA) indicating increased produc-
tion of toxic aldehydes in rats as previously reported [41]. 
This enhancement of lipid peroxidation products might 
be due to increased tissue damage, free radical produc-
tion and decreased hydrolysis of lipid peroxides [41]. 
APOP level was also increased in our study in 2K1C rats. 
We explored the protective mechanisms of sitagliptin by 
studying markers of oxidative stress and inflammation. 
Furthermore, sitagliptin treatment alone significantly 
enhanced the antioxidant enzyme activities and inhibited 
lipid peroxidation as compared to the sham rats. These 
findings support the premise that sitagliptin can guard 
against the sequences of oxidative stress.
Nitric oxide (NO) is sometime considered as another 
mediator of the oxidative stress. Nitric oxide may con-
vert into peroxinitrile which is much more dangerous 
than superoxide itself and causes more cellular damage in 
presence of superoxide free radicals. However, NO plays 
a significant role in the regulation of blood pressure and 
that impaired NO bioactivity is an important component 
of hypertension [42]. In our study, we also found that NO 
level increased in plasma of 2K1C rats which was nor-
malized by sitagliptin treatment. Previous study suggest 
Fig. 3 Effect of sitagliptin on cardiac fibrosis in 2K1C model rats. Picrosirius red staining for fibrosis. a Sham; b Sham + Sitagliptin; c 2K1C and d 
2K1C + Sitagliptin. No pathological collagen tissue deposition was observed in Sham animals (a) and Sham + Sitagliptin (b). Observe the greater 
collagen deposition in the left ventricle of heart of 2K1C rats (c arrows). No/less collagen tissue deposition can be observed in left ventricle of heart of 
all 2K1C animals treated with sitagliptin (d). Magnification ×40. fb fibrosis
Fig. 4 Effect of sitagliptin on kidney fibrosis in 2K1C model rats. a Sham; b Sham + Sitagliptin; c 2K1C and d 2K1C + Sitagliptin. No pathological 
collagen tissue deposition was observed in Sham animals (a) and Sham + Sitagliptin (b). Observe the greater collagen deposition in the left kidney 
of 2K1C rats (c arrows). No/less collagen tissue deposition can be observed in right kidney of all 2K1C animals treated with sitagliptin (d). Magnifica-
tion ×40. fb fibrosis
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that endothelial nitric oxide synthase (eNOS) and induc-
ible nitric oxide expression were increased in 2K1C rats 
[43]. Previous studies have also shown that iNOS iso-
forms are able to generate superoxide anions independ-
ent of NO production [44]. In our study, we also observed 
that AST, ALT, and ALP activities were increased signifi-
cantly in 2K1C rats. Sitagliptin treatment normalized 
these parameters which signify the overall improvement 
in health condition of the studied animals.
In cardiovascular remodeling, reactive free radical spe-
cies mediated oxidative stress and infiltration of inflam-
matory cells have been noticed in remodeled heart and 
implicates myocardial hypertrophy, fibrosis, conduction 
abnormalities and endothelial dysfunction which ulti-
mately leading to heart failure [45, 46]. Moreover, Ang-II 
promotes cardiac and kidney cell apoptosis and triggers 
fibrosis by activating the fibroblast cells and other growth 
mediators like TGF-β [47, 48]. Our study showed that 
massive collagen was deposited in both heart and kidney 
tissues. Sitagliptin supplementation attenuated this colla-
gen deposition as well as decreased the inflammation in 
these tissues.
Development and progression of nephropathy is 
another complication of diabetes which is primarily eval-
uated by glomerular hyperfiltration [49]. Moreover, acti-
vation of several metabolic pathways such as activation 
of protein kinase C [50], nonenzymatic glycosylation 
[51] acceleration of the polyol pathway [52], hexosamine 
biosynthetic pathway [53], and oxidative stress [54] are 
also involves in the development of diabetic nephropa-
thy. Further evidences are also pointing to a vital role 
of the inflammatory process in the development and 
progression of diabetic nephropathy [55–57]. Diverse 
inflammatory cells, including macrophages, mono-
cytes, and leukocytes, as well as other molecules, such 
as chemokines, adhesion molecules, and inflammatory 
cytokines, namely, tumor necrosis factor alpha (TNF-α) 
and interleukin-1β(IL-1β) [57–59] are few mediators of 
the inflammatory responses. If inflammation persists on, 
certain vascular lesions are aggravated, such as endothe-
lial dysfunction, tissue damage, renal fibrosis, and apop-
totic cell death [58, 59]. In our study, the wet weight of 
remnant kidney is significantly changed in treatment 
group when compared with sham rats. Moreover, our 
study suggests that sitagliptin supplementation also 
improved the uric acid and creatinin level in plasma of 
2K1C rats. Previous report suggests that 2K1C rat model 
showed significant increase in rennin activity and Ang-
II in circulating blood and tissues [60, 61]. Ang-II pro-
motes cardiac and kidney growth and in pathological 
condition this growth may turn into hypertrophy [62]. 
Moreover, in this model one kidney was clipped and 
other one set free to serve the whole body. To facilitate 
the whole body blood purification, this second kidney 
Fig. 5 Effect of sitagliptin on cardiac and kidney iron deposition in 2K1C model rats. a, e Sham; b, f Sham + Sitagliptin; c, g 2K1C and d, h 
2K1C + Sitagliptin. No pathological iron deposition was observed in left ventricle of heart (upper panel). Moreover, no pathological iron deposition 
was observed in kidneys of Sham animals (e) and Sham + Sitagliptin (f). Observe the greater iron deposition in the kidney of 2K1C rats (g arrows). 
No/less iron deposition can be observed in kidney of all 2K1C animals treated with sitagliptin (h). Magnification ×40. id  iron deposition
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adjusted itself and grows almost double. Previous report 
suggests that sitagliptin improves renal dysfunction and 
reduced glomerular and tubulointerstitial injury and 
exerts anti-oxidative, anti-apoptotic, and anti-inflamma-
tory effects [63].
Our study revealed the anti fibrotic activity of sitag-
liptin in heart and kidneys of 2K1C rats. The beneficial 
effect of sitagliptin was mainly due to the improvement 
of oxidative stress and inflammation in this rat model. 
Further research is required to establish clinical ben-
efit of sitagliptin in inflammation and fibrosis in diabetic 
hypertensive patients.
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